# EDGAR Filing Document

**Accession Number:** 0000856984
**File Stem:** 0001641172-25-018099
**Filing Date:** 2025-7
**Character Count:** 20056
**Document Hash:** 53164e9b0c4029dde5351b864c0aa16c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-018099.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001641172-25-018099

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20250708

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QHSLab, Inc.
- **CENTRAL INDEX KEY:** 0000856984
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112655906
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19041
- **FILM NUMBER:** 251109586

**BUSINESS ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407
- **BUSINESS PHONE:** (929) 379-6503

**MAIL ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITIES CORP.
- **DATE OF NAME CHANGE:** 20151119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITY CORP.
- **DATE OF NAME CHANGE:** 20151116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN BIOGENETIC SCIENCES INC
- **DATE OF NAME CHANGE:** 19940426

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (date of earliest event reported): July 8, 2025

**<u>QHSLab, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

---

| | |
|:---|:---|
| Nevada | 30-1104301 |
| (State<br> of Incorporation) | (I.R.S. Employer<br> Identification No.) |
| 901 Northpoint Parkway Suite 302 West Palm Beach<br> FL 33407 | 33407 |
| (Address of Principal Executive Offices) | (ZIP Code) |

---

Registrant's telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.0001 par value** | **USAQ** | **N/A** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (<u>https://twitter.com/qhslabinc</u>), LinkedIn account (<u>https://www.linkedin.com/company/65407282/</u>), Facebook account (<u>https://www.facebook.com/QHSLabs)</u> and Instagram account (<u>https://www.instagram.com/qhslabs/)</u> as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |

| 99.2 | [Press Release dated July 8, 2025 – QHS Healthcare, impulsado por QHSLab, Inc. (OTCQB: USAQ), abre sus puertas en Miami para ampliar el acceso a servicios de salud mental](ex99-2.htm)<br>|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: July 8, 2025 | Date: July 8, 2025 |
| QHSLab, Inc. | QHSLab, Inc. |
|  | */s/ Troy Grogan* |
| Name: | Troy Grogan |
| Title: | CEO and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

*Innovative initiative combines QHSLab's digital platform with on-site behavioral health services to advance timely, effective care.*

 

**MIAMI, FL, July 8, 2025 (GLOBE NEWSWIRE) — QHSLab Inc. (the "Company") (OTCQB: USAQ)**, a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, announced today the opening of its first co-branded QHS Behavioral Healthcare Center (QBHC) in Miami.

"This initiative will integrate modern, measurement-based digital screening and assessment technology with the human touch of in-person psychiatric and behavioral health services," said **Dr. Juan Oms**, Medical Director at QHS Healthcare and Psychiatric Medical Advisor to QHSLab, Inc. "We are excited to expand high-quality, patient-centered mental healthcare access in the Miami community, while maintaining clinical excellence and compassionate care. Setting a new standard in behavioral healthcare in the Miami area."

**Troy Grogan**, CEO of QHSLab, Inc., added:

"The QHS Behavioral Healthcare Centers will reinforce our mission to connect patients to the right care at the right time. This launch in Miami demonstrates how QHSLab's digital solutions can power a scalable network of brick-and-mortar care sites, enhancing engagement, continuity of care, and ultimately better outcomes. It is an important milestone for our shareholders, creating new revenue streams while supporting meaningful improvements in mental health."

**Ayesha Soto,** **CEO of QHS Healthcare:**

*"Our mission at QHS Healthcare is to deliver accessible, compassionate, and evidence-based behavioral health services to every patient who needs them. Partnering with QHSLab allows us to connect our high-quality in-person care with advanced digital technology, improving how we identify, engage, and support individuals with mental health needs. We are honored to serve the Miami community through this innovative collaboration."*

**Marcos Sanchez Gonzalez, MD, PhD**, Vice President of Medical and Scientific Affairs at QHSLab, Inc., commented:<br>

"By combining measurement-based screening, evidence-based interventions, and seamless care coordination, we believe QHS Healthcare can deliver a uniquely effective model of behavioral health. This benefits patients, communities, and our partners alike."

The QHS Behavioral Healthcare Center will be staffed by local mental health experts under a co-branded arrangement. This initiative directly aligns with QHSLab's commitment to patient-centric healthcare technologies and its mission to create scalable, community-based solutions that help address the nationwide mental health crisis.

**Value to Shareholders**

For USAQ shareholders, the launch of QHS Behavioral Healthcare Centers represents a significant strategic growth opportunity. This first center expands QHSLab's revenue streams beyond its core digital platform by licensing the brand and clinical processes, while maintaining patient engagement, brand equity, and technology adoption in local communities. By enabling a hybrid model of care, QHSLab positions itself at the forefront of digitally enabled behavioral health delivery.

For more information about QHSLab and our healthcare solutions, please visit <u>www.qhslab.com.</u>

**About QHSLab, Inc.**

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.

**About QHS Healthcare**

**Forward-Looking Statements**

Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Investor Relations Contact:**

Brett Maas, Managing Principal, Hayden IR, LLC

<u>brett@haydenir.com</u>

646-536-7331

<u>https://twitter.com/QHSLabInc</u>

## Exhibit 99.2

**Exhibit 99.2**

![](ex99-2_001.jpg)

**QHS Healthcare, impulsado por QHSLab, Inc. (OTCQB: USAQ), abre sus puertas en Miami para ampliar el acceso a servicios de salud mental**

*Una iniciativa innovadora combina la plataforma digital de QHSLab con servicios presenciales de salud conductual para mejorar el acceso oportuno y eficaz a la atención.*

 

**MIAMI, FL, 8 de julio de 2025 (GLOBE NEWSWIRE) — QHSLab Inc. (la "Compañía") (OTCQB: USAQ),** una empresa de salud digital que impulsa la medicina personalizada mediante innovadoras herramientas de monitoreo de salud poblacional y diagnóstico dentro de la atención primaria, anunció hoy la apertura de su primer Centro de Salud Conductual QHS (QBHC) con marca compartida en Miami.

Anunciado por primera vez en una carta a los accionistas el 16 de diciembre de 2024, este centro insignia representa una colaboración de marca compartida entre QHSLab y Global Behavioral Healthcare Group Corp, operando como QHS Healthcare Miami. Su misión es ofrecer una experiencia de atención continua e integrada para los pacientes identificados durante visitas rutinarias de atención primaria como necesitados de intervenciones especializadas en medicina conductual y del comportamiento. La colaboración tiene como objetivo garantizar que los pacientes accedan de forma oportuna y eficaz a servicios psiquiátricos y de salud mental de alta calidad, cerrando una brecha crítica en la atención de salud mental de la comunidad. La clínica funcionará con la gama completa de herramientas de medicina digital de QHSLab, que incluyen automatización inteligente, optimización de flujos de trabajo, documentación adaptativa y soporte de decisiones asistido por IA, posicionando a QBHC como clínica modelo para el futuro de la salud conductual y un ejemplo de cómo la medicina digital puede mejorar la operación y los resultados para los pacientes.

"Esta iniciativa integrará tecnología moderna de monitoreo y evaluación basada en mediciones con la atención presencial de servicios psiquiátricos y de salud conductual," comentó el **Dr. Juan Oms, Director Médico de QHS Healthcare** y Asesor Médico Psiquiátrico de QHSLab, Inc. "Estamos entusiasmados de ampliar el acceso a atención de salud mental de alta calidad, centrada en el paciente, para la comunidad de Miami, manteniendo la excelencia clínica y el cuidado compasivo. Con esta iniciativa estamos contemplamos un nuevo estándar para la atención de salud conductual en el área de Miami."

**Por otra parte, Troy Grogan, CEO de QHSLab, Inc.,** añadió:

"Los Centros de Salud Conductual QHS reforzarán nuestra misión de conectar a los pacientes con la atención adecuada en el momento adecuado. Este lanzamiento en Miami demuestra cómo las soluciones digitales de QHSLab pueden impulsar una red escalable de centros físicos, mejorando la participación del paciente, la continuidad de la atención y, en última instancia, los resultados. Es un hito importante para nuestros accionistas, creando nuevas fuentes de ingresos y apoyando mejoras significativas en la salud mental."

**Mientras, Ayesha Soto, CEO de QHS Healthcare**, expresó:

"Nuestra misión en QHS Healthcare es ofrecer servicios de salud conductual accesibles, compasivos y basados en la evidencia a todos los pacientes que los necesiten. Asociarnos con QHSLab nos permite conectar nuestra atención presencial de alta calidad con tecnología digital avanzada, mejorando la forma en que identificamos, comprometemos y apoyamos a las personas con necesidades de salud mental. Nos sentimos honrados de servir a la comunidad de Miami a través de esta colaboración innovadora."

El **Dr. Marcos Sánchez González, MD, PhD, Vicepresidente de Asuntos Médicos y Científicos de QHSLab, Inc.,** comentó:

"Al combinar monitoreo basado en mediciones, intervenciones basadas en evidencia y una coordinación fluida de la atención, creemos que QHS Healthcare puede ofrecer un modelo ejemplar de salud conductual verdaderamente eficaz. Esto beneficia a los pacientes, las comunidades y así como también a nuestros socios."

**Valor para los accionistas**

Para los accionistas de USAQ, el lanzamiento de los Centros de Salud Conductual QHS representa una oportunidad estratégica de crecimiento significativa. Este primer centro amplía las fuentes de ingresos de QHSLab más allá de su plataforma digital principal mediante la concesión de licencias de marca y procesos clínicos, al tiempo que mantiene el compromiso del paciente, el valor de la marca y la adopción de la tecnología en las comunidades locales. Al habilitar un modelo híbrido de atención, QHSLab se posiciona a la vanguardia de la prestación de salud conductual habilitada digitalmente.

**Acerca de QHSLab, Inc.**

QHSLab, Inc. (OTCQB: USAQ) es una empresa de tecnología médica y salud digital que ofrece soluciones de monitoreo remoto y salud conductual para ayudar a las prácticas de atención primaria a brindar atención basada en la evidencia, centrada en el paciente. Las soluciones de QHSLab mejoran la evaluación, optimizan la coordinación de la atención y ayudan a desbloquear nuevas oportunidades de reembolso, al tiempo que mejoran los resultados clínicos. Para más información, visite <u>www.qhslab.com</u>.

**Acerca de QHS Healthcare**

QHS Healthcare es una red de salud conductual de marca compartida impulsada por la tecnología de evaluación y coordinación de QHSLab. El centro combina servicios presenciales psiquiátricos y de salud conductual con herramientas digitales modernas, brindando atención accesible, de alta calidad y compasiva a las comunidades locales. Más información en <u>www.qhshealthcareg.com</u>.

**Declaraciones prospectivas**

Ciertos asuntos tratados en este comunicado de prensa constituyen "declaraciones prospectivas" destinadas a calificar para la protección legal establecida por la Ley de Reforma de Litigios sobre Valores Privados de 1995 (Private Securities Litigation Reform Act of 1995). En particular, las declaraciones de la Compañía relacionadas con tendencias en el mercado, ingresos futuros, productos futuros y resultados y adquisiciones potenciales son ejemplos de dichas declaraciones prospectivas. Las declaraciones prospectivas suelen identificarse con palabras como "puede," "podría," "cree," "estima," "objetivos," "espera," o "pretende," así como otras palabras similares que expresan riesgos e incertidumbres. Estas declaraciones están sujetas a numerosos riesgos e incertidumbres, que incluyen, entre otros, el momento de introducción de nuevos productos, la discrepancia inherente entre resultados reales y estimaciones, proyecciones y previsiones realizadas por la gerencia, demoras regulatorias, cambios en la financiación y presupuestos gubernamentales, y otros factores, incluidos las condiciones económicas generales, que están fuera del control de la Compañía. Los factores aquí expuestos y aquellos expresados ocasionalmente en los documentos presentados por la Compañía ante la Comisión de Bolsa y Valores (Securities and Exchange Commission) podrían hacer que los resultados y desarrollos reales difieran sustancialmente de los expresados o implícitos en dichas declaraciones. Las declaraciones prospectivas se realizan únicamente a la fecha de este comunicado de prensa. La Compañía no asume ninguna obligación de actualizar públicamente dichas declaraciones prospectivas para reflejar eventos o circunstancias posteriores.

**Contacto de Relaciones con Inversores:**

Brett Maas, Socio Director, Hayden IR, LLC

brett@haydenir.com<br> 646-536-7331<br> <u>https://twitter.com/QHSLabInc</u>